Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Dichloroacetic Acid, In a New Form | Main | A Look Back at Big Pharma Stocks »

March 27, 2014

Another Target Validation Effort

Email This Entry

Posted by Derek

Here's another target validation initiative, with GSK, the EMBL, and the Sanger Institute joining forces. It's the Centre for Therapeutic Target Validation (CCTV):

CTTV scientists will combine their expertise to explore and interpret large volumes of data from genomics, proteomics, chemistry and disease biology. The new approach will complement existing methods of target validation, including analysis of published research on known biological processes, preclinical animal modelling and studying disease epidemiology. . .

This new collaboration draws on the diverse, specialised skills from scientific institutes and the pharmaceutical industry. Scientists from the Wellcome Trust Sanger Institute will contribute their unique understanding of the role of genetics in health and disease and EMBL-EBI, a global leader in the analysis and dissemination of biological data, will provide bioinformatics-led insights on the data and use its capabilities to integrate huge streams of different varieties of experimental data. GSK will contribute expertise in disease biology, translational medicine and drug discovery.

That's about as much detail as one could expect for now. It's hard to tell what sorts of targets they'll be working on, and by "what sorts" I mean what disease areas, what stage of knowledge, what provenance, and everything else. But the press release goes on to say that the information gathered by this effort will be open to the rest of the scientific community, which I applaud, and that should give us a chance to look under the hood a bit.

It's hard for me to say anything bad about such an effort, other than wishing it done on a larger scale. I was about to say "other than wishing it ten times larger", but I think I'd rather have nine other independent efforts set up than making this one huge, for several reasons. Quis validet ipsos validares, if that's a Latin verb and I haven't mangled it: Who will validate the validators? There's enough trickiness and uncertainty in this stuff for plenty more people to join in.

Comments (11) + TrackBacks (0) | Category: Biological News | Drug Assays


COMMENTS

1. RealityCheck on March 27, 2014 9:48 AM writes...

This development has been eagerly anticipated at GSK and on the Genome Campus in Hinxton where both the Sanger and the EBI institutes are based. Though details are lacking at the moment, it undoubtedly represents a truly novel approach to bringing together synergistic and complementary skills sets for target validation. Going forward, it will be very interesting to see how it all plays out. Will this type of cross-fertilization create a totally new drug discovery ecosystem where public and private organizations can collaborate in the pre-competitive space to their mutual advantage? Patrick Vallance is a very energetic and eloquent advocate of this approach and is very well placed to provide the necessary impetus for this endeavour. Another interesting turn in the GSK journey!

Permalink to Comment

2. Faux sceptic on March 27, 2014 9:58 AM writes...

# RealityCheck

Thank you for reminding us (always) the vision and leader of the greats of this world.

Permalink to Comment

3. Anonymous on March 27, 2014 10:11 AM writes...

More investment in "bottom-up" drug discovery = more noise, less signal, more waste, less output.

Permalink to Comment

4. Anonymous on March 27, 2014 10:23 AM writes...

A somewhat metaphysical headline "Where do you start when developing a new medicine?
- Novel scientific collaboration to use genomics and big data to drive drug discovery" soon to be followed by "How do you start when developing a new medicine? Remind me" and then "Why bother starting to develop a new medicine ? Toothpaste is doing nicely thank you"

BTW I think CCTV is what they will be using to keep an eye on Hinxton ...

Permalink to Comment

5. Dr. Manhattan on March 27, 2014 11:53 AM writes...

It is worth remembering that GSK mounted a huge genomic effort in the antibiotic field about 15 years ago, found new targets, but in the end, they could not find compounds to productively interact with those targets and ultimately become drugs. Having a target is a start, but is far from an assurance of success.

I wish them the best, and would like to see some real success in translating genomics into effective compounds. I think, though, it is a very rough road to a drug, as this blog so often reminds us.

Permalink to Comment

6. luysii on March 27, 2014 1:43 PM writes...

What do you do when the target you've found from GWAS (Genome Wide Association Studies) turns out to be the pointer to the real target half a megaBase away? This actually happened. For details see https://luysii.wordpress.com/2014/03/26/why-drug-discovery-is-so-hard-reason-25-what-if-your-drug-target-is-really-a-pointer-to-the-real-target/

Permalink to Comment

7. Chris on March 27, 2014 2:32 PM writes...

I rather encouraged to see such endeavours starting, after all the publications we have seen on the lack of reproducibility of biological data an effort focused on target validation seems good news.

Whilst having a valid target is no guarantee of a drug candidate, working on an unvalidated target seems worse.

Permalink to Comment

8. sgcox on March 27, 2014 3:22 PM writes...

#luysii. Yes, that is a truly fascinating paper. Should be worth of a separate thread here.

Permalink to Comment

9. annonie on March 27, 2014 6:27 PM writes...

This is going to be another waste of time & resources sponsored by PV. So far, his judgment has been absolutely appalling, and there's no reason that this will be any better.

There is only one real way to conduct new target validation: having a compound in humans that selectivity interacts with an intended target that shows the desired effect.

Permalink to Comment

10. DrSnowboard on March 28, 2014 1:21 AM writes...

RealityCheck needs to google 'reality check' ....unless I've fallen prey to an extremely witty parody of PV's fanboy PR assistants.

Permalink to Comment

11. Classical Passerby on April 7, 2014 3:06 AM writes...

If there were a Latin verb "validare" with that meaning (and there's a modern Italian one, so sure, why the hell not), it'd be "Quis validat ipsos validatores?"

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All